Together with Noel Courage, MI's Philip Goldbach co-authored an article published in BioTechnology Focus on IP rights and considerations surrounding antibody-based assets. As the article states: Antibodies (immunoglobulins) and other antibody-derived…
MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses…
To coincide with our presence at the 2016 BIO International Convention (BIO) from June 6-9, 2016, MaRS Innovation launched a video explaining our role in Canada's innovation ecosystem: backing big…
The Journal of Clinical Chemistry recently hosted Dr. David Sinton of the University of Toronto in a podcast to highlight his work on commercializing technology for human sperm selection. Shatha…
Joel Liederman, vice-president of Physical Sciences, appeared on CanadaAM April 5, 2016 to talk about how to make a product. The interview is part of CanadaAM's "What's Next" segment on…
TORONTO (March 17, 2016) — QD Solar, a Canadian technology company created by the University of Toronto (U of T) and MaRS Innovation, has received $2.55 million from the Sustainable…
Prima IP co-sponsoring the Ryerson University and St. Michael’s Hospital event
That’s part of the reason why MaRS Innovation and Prima IP are sponsoring winners of an Angels’ Den competition involving the Institute for Biomedical Engineering, Science and Technology (iBEST).
iBEST is a partnership between Ryerson University and St. Michael’s Hospital that brings together Ryerson’s engineering and science strengths with St. Michael’s biomedical research and clinical expertise. The contest, which took place on June 26, 2015, riffs on the popular Dragon’s Den format.
“As a guest judge for the iBEST trainee competition this year, I reviewed a lot of thought-provoking ideas and MaRS Innovation congratulates all of the 2015 award winners,” says Dr. Fazila Seker, director of physical sciences. “Many of our portfolio technologies have their origins in this type of collaboration between researchers and medical staff, which is why we’re so excited to sponsor this competition. Fostering these types of relationships is vital to Toronto’s commercialization ecosystem.”
For the 2015 award period, MaRS Innovation will provide the competition’s winners with upfront commercialization consultation services to help shorten the time it may take for their ideas to reach the market. These services will be offered in collaboration with the technology transfer offices within St. Michael’s Hospital and the Vice-President of Research and Innovation office at Ryerson University as appropriate. In partnership with Prima IP, MaRS Innovation will also cover the initial patent application preparation and filing for the top two awardees of the iBEST event. Future award winners will receive similar support.
“Canada’s future economy depends on programs that encourage and facilitate innovation allowing Canada to remain competitive in the global marketplace and attract foreign investment,” said Marcelo König Sarkis, principal, founder and senior patent agent at Prima IP. “We are passionate in our support for Canadian inventions from the initial research phase to start-up and beyond.”
MaRS Innovation’s “model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding,” writes Thierry Heles in, “MaRS Innovation: A Unique Model for Tech Transfer,” for Global University Venturing.
This feature was also covered in Techopia.
The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.
Here’s an excerpt exploring the range of MI’s portfolio and Hofstein’s strategy for addressing technologies emerging in new areas:
In the beginning, Mars received primarily discoveries in the medical sector, but the balance has since shifted to 60% medically-oriented research and 40% for other areas. The medically-oriented discoveries, Hofstein elaborated, are a diverse set of technologies and include everything from drug development and molecular diagnostics to medical devices and healthcare IT.
The remaining 40% meanwhile cover “a smörgåsbord all the way from alternative energies and solar energy, and water reclamation to all sorts of mobile apps”.
Baycrest Heath Sciences’ “My Virtual Dream,” an innovative and interactive live performance experience at the intersection of science, art and music, is currently touring the installation with appearances in Amsterdam in May and more scheduled for Irvine, CA in October.
MaRS Innovation is working with the Baycrest team to commercialize the technology behind the demonstration, known as the virtual brain.
“The Virtual Dream tour is a ‘living lab’ that engages the public, fuels science, creates art and educates while it entertains,” says Richard Tavener, executive producer of the Virtual Dream tour.
The exhibition and research project was originally mounted in partnership with the University of Toronto, Nuit Blanche 2013, and InteraXon and also made a January 2015 appearance at the Ontario Science Centre.
Participants wear the Muse, a brain-computer interface headset provided by InteraXon, and use focus and mental relaxation states to complete a science game and create a stunning array of visuals and music.
The brain data collected at Nuit Blanche has yielded insights about how the brain learns and a science paper about this massive, one-night neuroscience experiment. The paper, which appeared in the July issue of PLOS One, found that:
MaRS Innovation and its member institutions are is profiled in International Innovation‘s July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI’s president and CEO, written by Rosemary Peters.
The article is posted on the publication’s website and viewable through a digital interface (pages 80 and 81).
Here’s an excerpt from Dr. Hofstein’s comments:
“Canada’s academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the U.K. While this remains a matter of debate, I do agree that we need to continually encourage additional sources of seed capital to join is so as to allow for accelerated advancement of early-stage technologies. Industry needs to become much more engaged in advancing early-stage (and promising!) technologies emerging from the academic sector, which are usually young and in significant attention, navigation, management expertise and seed capital provisions. These are areas of rising importance in Canada, as many innovations fall into the ‘valley of death’ due to a lack of proper funding, or they leave the country and flourish in the U.S. where funding is more abundant.